Germany Cardiac Biomarker Market is estimated to grow significantly at a CAGR of around 7.5% during the forecast period. The market mainly is driven due to due to the massive population of CVD, CHD &stroke and rise in adoption of a cardiac biomarker for the diagnosis of CVD and other heart related diseases. The demand for cardiac biomarker tests for Myocardial infarction, Acute coronary syndrome, and heart failure are increasing significantly and boosting the market growth. According to the Global Burden of Disease database, Germany accounted for more about 1.03 million new cases of CVD in 2010 that increased to about 1.08 million in 2015. Adoption of specialized procedures to treat CVDs such as biomarkers, extensive R&D in the CVDs diagnosis and presence of globally renowned major hospitals, research centers and clinics are contributing to the growth of the market
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/germany-cardiac-biomarker-market
The market is segmented on the basis of type, application, and location of testing. Based on type, the market is segregated into Creatine kinase (CK-MB), Troponins (T, I), Myoglobin, Natriuretic peptides (BNP & NT-PROBNP), Ischemia modified albumin and Others. The troponin is anticipated to be the fastest growing and has a considerable market share in the Germany cardiac biomarker market due to easy and high sensitivity that results in the high adoption of the test. Based on application, the market is segmented into myocardial infraction, congestive heart failure, acute coronary syndrome, atherosclerosis, and others. On the basis of the location of testing, the market is classified into laboratory testing and point of care testing.
Browse for Full Report Description@ https://www.omrglobal.com/industry-reports/germany-cardiac-biomarker-market
The companies which are contributing to the growth of the Germany cardiac biomarker market include Abbott Laboratories, BioMérieux S.A., Cisbio Bioassays SAS, Danaher Corp., F. Hoffmann-La Roche AG, HyTest Ltd, Merck KGaA, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups and technological advancements to stay competitive in the market.
Market Segmentation
By Type
- Creatine kinase (CK-MB)
- Troponins(T,I)
- Myoglobin
- Natriuretic peptides (BNP & NT-PROBNP)
- Ischemia modified albumin
- Others
By Application
- Myocardial infraction
- Congestive heart failure
- Acute coronary syndrome
- Atherosclerosis
- Others
By Location of Testing
- Laboratory testing
- Point of care testing
Company Profiles
- Abbott Laboratories
- BioMérieux S.A.
- Cisbio Bioassays SAS
- Danaher Corp.
- Hoffmann-La Roche AG
- HyTest Ltd
- Merck KGaA
- Randox Laboratories Ltd.
- Siemens Healthcare GmbH
- Thermo Fisher Scientific Inc.
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
